Atrin Pharmaceuticals
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Atrin Pharmaceuticals was a Doylestown, Pennsylvania biotech founded in 2012 by Oren Gilad, discovering and developing novel therapeutics targeting proteins in the DNA damage response pathway through synthetic lethality for cancer. Its lead program, ATRN-119, was a clinical-stage small-molecule ATR inhibitor for solid tumors. The company was acquired by Aprea Therapeutics in May 2022.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Oren Gilad founds Atrin Pharmaceuticals in Doylestown, Pennsylvania to pursue DNA damage response drug discovery through synthetic lethality.
- Acquisition
Aprea Therapeutics acquires Atrin in May 2022 and shifts its primary focus to the ATR inhibitor ATRN-119 in Phase 1/2a solid-tumor trials.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.